2025
308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-308-or.Peer-Reviewed Original ResearchDipeptidyl peptidase-4 inhibitorsIncident cancer riskSodium-glucose cotransporter 2 inhibitorsIncident cancerGLP-1RACancer riskHigher risk of incident cancerType 2 diabetesRisk of incident cancerHigh riskReceptor agonistsMedicare fee-for-serviceFemale breast cancerFee-for-serviceGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsPropensity score inverse probabilityTarget trial emulationModerate CVD riskCox proportional hazards modelsOptumLabs Data WarehousePeptidase-4 inhibitorsIncidence of melanomaAdverse cardiovascular events
2015
Melanoma in situ Part I. Epidemiology, screening, and clinical features
Higgins HW, Lee KC, Galan A, Leffell DJ. Melanoma in situ Part I. Epidemiology, screening, and clinical features. Journal Of The American Academy Of Dermatology 2015, 73: 181-190. PMID: 26183967, DOI: 10.1016/j.jaad.2015.04.014.Peer-Reviewed Original ResearchConceptsClinical featuresPart I. EpidemiologyReview of melanomaUnderstanding of melanomaIncidence of melanomaMedical education articleI. EpidemiologyClinical outcomesTreatment optionsClinical managementRisk factorsMalignant melanomaBiologic behaviorClinical studiesMelanomaEpidemiologyIncidenceHigh percentageEducation articlesHistopathologyPathology
2014
Point of care cutaneous imaging technology in melanoma screening and mole mapping
Higgins HW, Lee KC, Leffell DJ. Point of care cutaneous imaging technology in melanoma screening and mole mapping. F1000Research 2014, 6: 34. PMID: 24860656, PMCID: PMC4017910, DOI: 10.12703/p6-34.Peer-Reviewed Original ResearchDiagnosis of melanomaSkin cancer-related deathsRoutine skin cancer screeningMalignancy of melanocytesCancer-related deathIncidence of melanomaSkin cancer screeningCancer screeningEarly diagnosisSkin cancerMelanomaMelanoma screeningPigment-producing cellsDiagnostic discriminationEarly detectionDiagnosisHandheld magnifiersScreeningMorbidityMalignancyCancerGreater numberMortalityIncidencePhysicians
2009
Chemotherapy and biologic therapies for melanoma: do they work?
Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clinics In Dermatology 2009, 27: 614-625. PMID: 19880049, DOI: 10.1016/j.clindermatol.2008.09.020.Peer-Reviewed Original ResearchConceptsResponse rateMinority of patientsSubset of patientsInterleukin-2 (IL-2) resultsImproved response ratesIncidence of melanomaIdentification of predictorsCombination of agentsUnresectable diseaseBiologic therapyOlder regimensOverall survivalStandard chemotherapyTherapeutic optionsClinical trialsNew agentsSmall molecule inhibitorsSingle agentImmune systemMonoclonal antibodiesDeath rateMelanomaMalignant melanocytesChemotherapyMolecule inhibitors
1995
Multiple Primary Melanomas
Ariyan S, Poo W, Bolognia J, Buzaid A, Ariyan T, Ariyan S. Multiple Primary Melanomas. Plastic & Reconstructive Surgery 1995, 96: 1384-1389. PMID: 7480238, DOI: 10.1097/00006534-199511000-00023.Peer-Reviewed Original ResearchConceptsSecond primary melanomaPrimary melanomaPrimary cutaneous melanomaMultiple primary melanomasIncidence of melanomaYale Melanoma UnitFirst malignancySubsequent melanomaFirst diagnosisPoor prognosisCutaneous melanomaMelanoma UnitPatient prognosisMultiple melanomasSubsequent lesionsPatientsInitial melanomaMelanomaPrognosisFirst yearSecond yearReportYearsMalignancyStatistics Report
1991
Time trends in malignant melanoma of the upper limb in Connecticut
Dubrow R, Flannery J, Liu W. Time trends in malignant melanoma of the upper limb in Connecticut. Cancer 1991, 68: 1854-1858. PMID: 1913533, DOI: 10.1002/1097-0142(19911015)68:8<1854::aid-cncr2820680837>3.0.co;2-c.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply